Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Bristol-Myers Squibb Company (BMY). You can receive reports or configure the research engine for yourself.
Report On:
Bristol-Myers Squibb Company (BMY)
HEALTHCARE - Drugs - Drug Manufacturers - Major
Generated: Thursday September 15, 2011 04:05 AM
|
|
||||||||||||||||||
Quotes About Bristol-Myers Squibb Company
-
Surveyed U.S. Cardiologists Say That Superior Stroke Prevention Efficacy and Less Major Bleeding Than Warfarin Would Pro
This clinical scenario of apixaban, as recently demonstrated in the drug's pivotal ARISTOTLE trial, stands to profoundly alter the competitive dynamics of the atrial fibrillation drug market as well as the fortunes of rival agents Xarelto and Pradaxa," -
R&D Council Selects Thomas Alva Edison Patent Award Winners for 2011
The Council established the Thomas Alva Edison Patent Award to ensure that the significant and diverse research and development work done by scientists and their respective New Jersey organizations receives the superstar recognition it deserves in this state,"
- Ian Shankland -
NCC Receives Bristol-Myers Squibb Foundation Grant For Its Peru Program
This Bristol-Myers Squibb Foundation support complements the innovative BD sponsored SurePath™ liquid-based Pap program that NCC and our partner CerviCusco clinic have begun implementing to test 75,000 women in this region of Peru over the next three years."
- Robert Landry -
Amira spins out programs with $475M BMS buyout
Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program,"
- Bob Baltera -
Marshall receives $2.6 million for diabetes programs
Study after study has shown that we have an alarming situation with type 2 diabetes in the areas served by the Marshall University Center for Rural Health,"
No Comment
-
Drug Contract Manufacturer Ben Venue To Exit Business
Spokesmen for Bristol and Pfizer declined to comment .
- Peter Loftus
Latest Company Intelligence
-
(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data
Stock Market Blog | Sep 14,'11
Recently, Bristol-Myers Squibb Company ( BMY ) and partner Pfizer ( PFE ) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional risk factor for stroke. The cardiac rhythm disorder is referred to as atrial fibrillation -
Pfizer: Trouble Ahead in Post-Lipitor World, Says Analyst
Stocks To Watch Today | Sep 14,'11
As Pfizer ( PFE ) faces the expiration of its patent on Lipitor and no likely blockbuster announcements in the near-future, the stock could be stuck in a holding pattern, writes Barclays analyst C. Anthony Butler in downgrading the stock to Equal Weight from Overweight. “Through year's end, we foresee limited potential for upside surprises from R&D catalysts,” he writes. “Top-line -
Director of Bristol-Myers-Squibb to Run Weill Cornell Medical School
Health Care Renewal | Sep 13,'11
How the New York Times reported on a change in leadership at one New York medical school has made one issue of interest to Health Care Renewal a bit less anechoic . Here is the beginning of the story : A Harvard University researcher and professor with strong ties to the pharmaceutical industry has been selected as the new dean of Weill Cornell Medical College in Manhattan, as Cornell -
Can This High-Yielding Healthcare Stock Sustain Its Dividend?
Seeking Alpha | Sep 12,'11
Currently yielding a large 4.50% and trading at a reasonable 15 times earnings, Bristol Myers-Squibb ( BMY ) has been a good place for income investors to park their cash and get paid. There is significant worry, however, in the minds of investors. While the company showed solid growth in the second quarter of 2011, the company is facing patent expiration for Plavix (its heart attack -
Latest in Stroke-Prevention Saga: FDA Panel Backs Drug From J&J and Bayer
Xconomy | Sep 9,'11
Yesterday I wrote about apixaban (Eliquis), a drug that Bristol-Myers Squibb (NYSE: BMY ) and Pfizer (NYSE: PFE ) are developing to prevent strokes in patients with the heart-rhythm disorder atrial fibrillation . The folks at Bristol were paying close attention to a meeting at the FDA yesterday, during which an advisory panel to the agency voted on whether it should approve a -
Johnson & Johnson, Bristol-Myers: Investment Implications Of Rivararoxban's FDA Problems
Seeking Alpha | Sep 8,'11
The FDA problems encountered with rivaroxaban are a significant, but not crushing, negative for the investment thesis of Johnson & Johnson ( JNJ ). I would still be buyer of the stock as JNJ is a very large company, not overly dependent on any one current or future product, that still has an excellent new drug product outlook even without rivaroxaban. I have been on the fence in deciding
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
